128 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp07668 | Longicalycinin A linear analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.66 ± 0.0007 µg/ml |
| dbacp07669 | Longicalycinin A linear analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.45 ± 0.0042 µg/ml |
| dbacp07670 | Longicalycinin A linear analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 13.29% Cell death at 100 µg/ml |
| dbacp07671 | Longicalycinin A linear analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 83.02% Cell death at 100 µg/ml |
| dbacp07672 | Longicalycinin A Cyclic analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.2 ± 0.007 µg/ml |
| dbacp07673 | Longicalycinin A Cyclic analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.4 ± 0.0028 µg/ml |
| dbacp07674 | Longicalycinin A Cyclic analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 69.73% Cell death at 100 µg/ml |
| dbacp07675 | Longicalycinin A Cyclic analogue 1 | GYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 71.5% Cell death at 100 µg/ml |
| dbacp07676 | Longicalycinin A linear analogue 2 | LYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 8.76 ± 0.0035 µg/ml |
| dbacp07677 | Longicalycinin A linear analogue 2 | LYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.33 ± 0 µg/ml |
| dbacp07678 | Longicalycinin A linear analogue 2 | LYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 71.37% Cell death at 100 µg/ml |
| dbacp07679 | Longicalycinin A linear analogue 2 | LYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 88.47% Cell death at 100 µg/ml |
| dbacp07687 | Longicalycinin A linear analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.67 ± 0.0007 µg/ml |
| dbacp07688 | Longicalycinin A linear analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 9.12 ± 0.0042 µg/ml |
| dbacp07689 | Longicalycinin A linear analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 13.02% Cell death at 100 µg/ml |
| dbacp07690 | Longicalycinin A linear analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 82.36% Cell death at 100 µg/ml |
| dbacp07691 | Longicalycinin A cyclic analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.46 ± 0.0028 µg/ml |
| dbacp07692 | Longicalycinin A cyclic analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.92 ± 0.0021 µg/ml |
| dbacp07693 | Longicalycinin A cyclic analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 70.69% Cell death at 100 µg/ml |
| dbacp07694 | Longicalycinin A cyclic analogue 14 | PYFFL | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 52.38% Cell death at 100 µg/ml |
| dbacp07695 | Longicalycinin A linear analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.77 ± 0.0007 µg/ml |
| dbacp07696 | Longicalycinin A linear analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.4 ± 0 µg/ml |
| dbacp07697 | Longicalycinin A linear analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 82.33% Cell death at 100 µg/ml |
| dbacp07698 | Longicalycinin A linear analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 87.56% Cell death at 100 µg/ml |
| dbacp07699 | Longicalycinin A cyclic analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.5 ± 0.0056 µg/ml |
| dbacp07700 | Longicalycinin A cyclic analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.28 ± 0.0063 µg/ml |
| dbacp07701 | Longicalycinin A cyclic analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 56.72% Cell death at 100 µg/ml |
| dbacp07702 | Longicalycinin A cyclic analogue 3 | GYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 28.51% Cell death at 100 µg/ml |
| dbacp07703 | Longicalycinin A linear analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.53 ± 0.0014 µg/ml |
| dbacp07704 | Longicalycinin A linear analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.78 ± 0.0021 µg/ml |
| dbacp07705 | Longicalycinin A linear analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 27.13% Cell death at 100 µg/ml |
| dbacp07706 | Longicalycinin A linear analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 75.91% Cell death at 100 µg/ml |
| dbacp07707 | Longicalycinin A cyclic analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.77 ± 0.007 µg/ml |
| dbacp07708 | Longicalycinin A cyclic analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.33 ± 0.0035 µg/ml |
| dbacp07709 | Longicalycinin A cyclic analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 71.1% Cell death at 100 µg/ml |
| dbacp07710 | Longicalycinin A cyclic analogue 4 | AYPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 52.49% Cell death at 100 µg/ml |
| dbacp07711 | Longicalycinin A linear analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 8.99 ± 0.0014 µg/ml |
| dbacp07712 | Longicalycinin A linear analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.97 ± 0.0049 µg/ml |
| dbacp07713 | Longicalycinin A linear analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 76.72% Cell death at 100 µg/ml |
| dbacp07714 | Longicalycinin A linear analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 91.52% Cell death at 100 µg/ml |
| dbacp07715 | Longicalycinin A cyclic analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.45 ± 0.0056 µg/ml |
| dbacp07716 | Longicalycinin A cyclic analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 9.98 ± 0.4256 µg/ml |
| dbacp07717 | Longicalycinin A cyclic analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 41.37% Cell death at 100 µg/ml |
| dbacp07718 | Longicalycinin A cyclic analogue 5 | FSPFG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 97.74% Cell death at 100 µg/ml |
| dbacp07719 | Longicalycinin A linear analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.98 ± 0.0014 µg/ml |
| dbacp07720 | Longicalycinin A linear analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.31 ± 0.0063 µg/ml |
| dbacp07721 | Longicalycinin A linear analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 38.64% Cell death at 100 µg/ml |
| dbacp07722 | Longicalycinin A linear analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 49.33% Cell death at 100 µg/ml |
| dbacp07723 | Longicalycinin A cyclic analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 17.34 ± 0.0014 µg/ml |
| dbacp07724 | Longicalycinin A cyclic analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.2 ± 0.0021 µg/ml |
| dbacp07725 | Longicalycinin A cyclic analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 51.79% Cell death at 100 µg/ml |
| dbacp07726 | Longicalycinin A cyclic analogue 6 | VYPIA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 27.61% Cell death at 100 µg/ml |
| dbacp07727 | Longicalycinin A linear analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.6 ± 0.0007 µg/ml |
| dbacp07728 | Longicalycinin A linear analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 9.78 ± 0.0212 µg/ml |
| dbacp07729 | Longicalycinin A linear analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 82.33% Cell death at 100 µg/ml |
| dbacp07730 | Longicalycinin A linear analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 84.17% Cell death at 100 µg/ml |
| dbacp07731 | Longicalycinin A cyclic analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.21 ± 0.0056 µg/ml |
| dbacp07732 | Longicalycinin A cyclic analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.11 ± 0.0035 µg/ml |
| dbacp07733 | Longicalycinin A cyclic analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 47.68% Cell death at 100 µg/ml |
| dbacp07734 | Longicalycinin A cyclic analogue 7 | PYVFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 22.86% Cell death at 100 µg/ml |
| dbacp07735 | Longicalycinin A linear analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.35 ± 0.0014 µg/ml |
| dbacp07736 | Longicalycinin A linear analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.88 ± 0.0014 µg/ml |
| dbacp07737 | Longicalycinin A linear analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 15.35% Cell death at 100 µg/ml |
| dbacp07738 | Longicalycinin A linear analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 88.01% Cell death at 100 µg/ml |
| dbacp07739 | Longicalycinin A cyclic analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.12 ± 0.0007 µg/ml |
| dbacp07740 | Longicalycinin A cyclic analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.67 ± 0.0028 µg/ml |
| dbacp07741 | Longicalycinin A cyclic analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 36.85% Cell death at 100 µg/ml |
| dbacp07742 | Longicalycinin A cyclic analogue 8 | FYPVG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 29.87% Cell death at 100 µg/ml |
| dbacp07743 | Longicalycinin A linear analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.33 ± 0.0007 µg/ml |
| dbacp07744 | Longicalycinin A linear analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.44 ± 0.5536 µg/ml |
| dbacp07745 | Longicalycinin A linear analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 72.74% Cell death at 100 µg/ml |
| dbacp07746 | Longicalycinin A linear analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 1.59% Cell death at 100 µg/ml |
| dbacp07747 | Longicalycinin A cyclic analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.67 ± 0 µg/ml |
| dbacp07748 | Longicalycinin A cyclic analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.7 ± 0.0056 µg/ml |
| dbacp07749 | Longicalycinin A cyclic analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 73.98% Cell death at 100 µg/ml |
| dbacp07750 | Longicalycinin A cyclic analogue 9 | FYPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 76.25% Cell death at 100 µg/ml |
| dbacp07751 | Longicalycinin A linear analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.5 ± 0.0014 µg/ml |
| dbacp07752 | Longicalycinin A linear analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.5 ± 0.0007 µg/ml |
| dbacp07753 | Longicalycinin A linear analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 76.72% Cell death at 100 µg/ml |
| dbacp07754 | Longicalycinin A linear analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 92.09% Cell death at 100 µg/ml |
| dbacp07755 | Longicalycinin A cyclic analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.28 ± 0 µg/ml |
| dbacp07756 | Longicalycinin A cyclic analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.56 ± 0.0028 µg/ml |
| dbacp07757 | Longicalycinin A cyclic analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 72.06% Cell death at 100 µg/ml |
| dbacp07758 | Longicalycinin A cyclic analogue 10 | FYPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 71.27% Cell death at 100 µg/ml |
| dbacp07759 | Longicalycinin A linear analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.56 ± 0.0021 µg/ml |
| dbacp07760 | Longicalycinin A linear analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.67 ± 0.0014 µg/ml |
| dbacp07761 | Longicalycinin A linear analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 70.28% Cell death at 100 µg/ml |
| dbacp07762 | Longicalycinin A linear analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 88.47% Cell death at 100 µg/ml |
| dbacp07763 | Longicalycinin A cyclic analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.36 ± 0 µg/ml |
| dbacp07764 | Longicalycinin A cyclic analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.61 ± 0.0007 µg/ml |
| dbacp07765 | Longicalycinin A cyclic analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 72.06% Cell death at 100 µg/ml |
| dbacp07766 | Longicalycinin A cyclic analogue 11 | TVPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 74.89% Cell death at 100 µg/ml |
| dbacp07767 | Longicalycinin A linear analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 11.32 ± 0.0014 µg/ml |
| dbacp07768 | Longicalycinin A linear analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 14.2 ± 0.0014 µg/ml |
| dbacp07769 | Longicalycinin A linear analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 12.06% Cell death at 100 µg/ml |
| dbacp07770 | Longicalycinin A linear analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 81.34% Cell death at 100 µg/ml |
| dbacp07771 | Longicalycinin A cyclic analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 12.37 ± 0.0014 µg/ml |
| dbacp07772 | Longicalycinin A cyclic analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 13.2 ± 0 µg/ml |
| dbacp07773 | Longicalycinin A cyclic analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 63.84% Cell death at 100 µg/ml |
| dbacp07774 | Longicalycinin A cyclic analogue 12 | FYPFI | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 52.72% Cell death at 100 µg/ml |
| dbacp07775 | Longicalycinin A cyclic analogue 15 | PYGFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.33 ± 0 µg/ml |
| dbacp07776 | Longicalycinin A cyclic analogue 15 | PYGFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.23 ± 0.0007 µg/ml |
| dbacp07777 | Longicalycinin A cyclic analogue 15 | PYGFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 52.33% Cell death at 100 µg/ml |
| dbacp07778 | Longicalycinin A cyclic analogue 15 | PYGFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 27.43% Cell death at 100 µg/ml |
| dbacp07779 | Longicalycinin A linear analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 11.1 ± 0.0007 µg/ml |
| dbacp07780 | Longicalycinin A linear analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 12.11 ± 0.0056 µg/ml |
| dbacp07781 | Longicalycinin A linear analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 15.76% Cell death at 100 µg/ml |
| dbacp07782 | Longicalycinin A linear analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 88.24% Cell death at 100 µg/ml |
| dbacp07783 | Longicalycinin A cyclic analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 12.1 ± 0.0007 µg/ml |
| dbacp07784 | Longicalycinin A cyclic analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.4 ± 0.0028 µg/ml |
| dbacp07785 | Longicalycinin A cyclic analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 42.33% Cell death at 100 µg/ml |
| dbacp07786 | Longicalycinin A cyclic analogue 16 | FTPFV | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 29.87% Cell death at 100 µg/ml |
| dbacp07787 | Longicalycinin A linear analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.33 ± 0.0007 µg/ml |
| dbacp07788 | Longicalycinin A linear analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.33 ± 0.0035 µg/ml |
| dbacp07789 | Longicalycinin A linear analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 27.54% Cell death at 100 µg/ml |
| dbacp07790 | Longicalycinin A linear analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 75.68% Cell death at 100 µg/ml |
| dbacp07791 | Longicalycinin A cyclic analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.4 ± 0.0014 µg/ml |
| dbacp07792 | Longicalycinin A cyclic analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 11.2 ± 0.0007 µg/ml |
| dbacp07793 | Longicalycinin A cyclic analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 74.53% Cell death at 100 µg/ml |
| dbacp07794 | Longicalycinin A cyclic analogue 17 | FSPFA | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 76.14% Cell death at 100 µg/ml |
| dbacp07795 | Longicalycinin A linear analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 10.33 ± 0.0007 µg/ml |
| dbacp07796 | Longicalycinin A linear analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 10.2 ± 0.0014 µg/ml |
| dbacp07797 | Longicalycinin A linear analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 15.55% Cell death at 100 µg/ml |
| dbacp07798 | Longicalycinin A linear analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | 56.51% Cell death at 100 µg/ml |
| dbacp07799 | Longicalycinin A cyclic analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | IC50 = 9.68 ± 0.0014 µg/ml |
| dbacp07800 | Longicalycinin A cyclic analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colorectal Cancer | IC50 = 9.06 ± 0.0014 µg/ml |
| dbacp07801 | Longicalycinin A cyclic analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HepG-2 | Liver Cancer | 46.58% Cell death at 100 µg/ml |
| dbacp07802 | Longicalycinin A cyclic analogue 18 | FSPAG | Synthetic Analogue of Longicalycinin A | Cyclization enhances apoptosis via lysosomes | MTT assay | HT-29 | Colon Cancer | 22.8% Cell death at 100 µg/ml |